Investor Relations

The information in this Investor Relations section is being disclosed for the purposes of AIM Rule 26.

Originally founded in 1987, Omega Diagnostics Group PLC was established in September 2006 when Omega Diagnostics Limited completed a “reverse acquisition” of an AIM Listed Cash Shell Company called Quintessentially English PLC.


Investor Relations


We are focused on selling a range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market.

Since listing in 2006, we have combined an organic and acquisitive growth strategy to establish a significant presence in its chosen product  and geographic areas.

A focus on specific, specialised product categories together with a core competency  of export sales has allowed us to establish a strong sales track record.

Originally founded as Omega Diagnostics Ltd in Scotland, our global reputation stems from beginnings as a manufacturer of tests for a range of infectious diseases such as syphilis, tuberculosis, dengue fever, chagas disease and malaria. Our export success was officially recognised with the Queen’s Award for Export Achievement in 1993, providing a solid foundation for future success.

Our product range was extended following the acquisition of Genesis Diagnostics Ltd and Cambridge Nutritional Sciences Ltd in September 2007 giving our customers access to tests for the fast growing area of food intolerance testing.

In 2010, we acquired the IVD division of allergy and specific immunotherapy specialist Allergopharma Joachim Ganzer KG, giving further access to a range of allergy tests for over 600 allergens. This gave us a position in allergy testing that could be exploited in two ways. First, by driving international sales of current products through its existing global distribution network; and second by delivering a panel of automated allergy tests in conjunction with Immunodiagnostics Systems’ IDS-iSYS platform.

In the following year, the group founded a wholly-owned subsidiary based in Mumbai, India providing access to the Indian market for the sale and distribution for the Group companies' products.

In 2012, we announced that we has entered into agreements providing worldwide exclusive access to two point of care (POC) tests for CD4 and Syphilis developed by Burnet Institute in Melbourne, Australia. Testing for the number of CD4 T+ cells is a vital component for the management and care of people suffering from HIV and is required to determine when HIV patients should commence antiretroviral treatment (ART). The current market for monitoring of CD4 T+ cells is dominated by expensive and complex technology which is a bottleneck to commencing ART particularly for HIV patients living in rural areas. There is a clear unmet need for a lower cost POC test that can be conducted in doctors' surgeries and outreach clinics in resource-poor settings.

In 2018, a restructure of our operations was carried out whereby our four UK companies were amalgamated into one entity, Omega Diagnostics Ltd. Further to this, in 2018 we disposed of our infectious disease business, with the exception of VISITECT CD4, to Novacyt SA, an international specialist in clinical diagnostics.

In early 2022, we implemented a revised strategy to reduce operating costs through the sale of the Alva site, exit the Global Health business and to invest in our Health and Nutrition business in order to drive growth. We are now focused on creating value by increasing the footprint of our food sensitivity products, particularly in the US and China, where we see opportunities for growth in direct-to-consumer market channels and broadening the range of products available in our Health and Nutrition division.

Shares in the Company are not traded anywhere other than AIM

Last updated 30 September 2022